Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court

This article was originally published in The Tan Sheet

Executive Summary

The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophy
Advertisement

Related Content

Class Action Feeding Frenzy Could Chill On Legislation, Judicial Shift
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Saw Palmetto denial
Saw Palmetto denial
Saw Palmetto denial
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
Saw Palmetto En Banc Appeals Court Re-Hearing Requested
FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court

Topics

Advertisement
UsernamePublicRestriction

Register

PS096384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel